Compare FirstEnergy Corp. (FE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs TG Therapeutics Inc — how do they compare? FirstEnergy Corp. trades at $48.58 (market cap $28.13B), while TG Therapeutics Inc trades at $54.82 (market cap $8.64B). The key difference: FirstEnergy Corp. is far larger — about 3.3× TG Therapeutics Inc's market cap, and FirstEnergy Corp. pays a 3.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FE | TGTX | |
|---|---|---|
Market Cap | $28.13B | $8.64B |
Sector | Utilities | Health |
52-Week High | $51.91 | $59.06 |
52-Week Low | $40.30 | $26.39 |
Enterprise Value | $56.14B | $8.88B |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy Corp. (FE) trades at $49.17, down 0.1% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue growth is steady at $15.09 billion for 2025. The company benefits from rising data center demand and a $36 billion investment plan, highlighted by recent news of grid upgrades and leadership appointments to drive operational performance.
Outlook is positive with a consensus price target of $52.00, offering ~6% upside. Key opportunities include infrastructure investments and data center growth, but risks involve high debt levels and regulatory pressures. Institutional sentiment is bullish with no sell ratings, though net cash flow remains negative, requiring careful monitoring of capital expenditures.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
